Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.39 |
| ▸ | BAD | Q92934 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | HPN | P05981 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30042387 | 1.00 | BCL2L1 (0.39) | BCL2L1BADALDH1A1ALOX15HSD17B10 | |
| Hydrochloric Acid SCHEMBL28866187 | 0.98 | BCL2L1 (0.38) | BCL2L1BADALDH1A1ALOX15HSD17B10 | |
| SCHEMBL4445125 | 0.78 | BCL2L1 (0.41) | BCL2L1BADALDH1A1ALOX15HSD17B10 | |
| SCHEMBL7450666 | 0.78 | BCL2L1 (0.36) | BCL2L1BADALDH1A1ALOX15HSD17B10 | |
| SCHEMBL2783384 | 0.77 | CA1 (0.32) | CA2CA1 | |
| SCHEMBL30183336 | 0.77 | CA1 (0.32) | CA2CA1 | |
| SCHEMBL23668366 | 0.77 | CYP3A4 (0.41) | ALDH1A1HSD17B10CYP3A4MAPTTSHR | |
| Lithium SCHEMBL29767672 | 0.76 | CA1 (0.32) | CA2CA1 | |
| SCHEMBL28432571 | 0.76 | CA1 (0.32) | CA2CA1 | |
| SCHEMBL277191 | 0.74 | CA1 (0.33) | CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105732307-B | The synthetic method of Maxacalcitol intermediate | 科贝源(北京)生物医药科技有限公司 | 2019-04-19 | — | — | CN | claimed |
| CN-105209429-B | SHIP1 conditioning agents and relative method | 阿奎诺克斯药物（加拿大）公司 | 2018-05-29 | — | — | CN | claimed |
| US-20250241872-A1 | AFFINITY MEDICANT CONJUGATE | Illudent, Inc. (US) | 2025-07-31 | — | — | US | disclosed |
| US-12280021-B2 | Affinity medicant conjugate | AF CHEMICALS, LLC (US) | 2025-04-22 | — | — | US | disclosed |
| US-20230372267-A1 | AFFINITY MEDICANT CONJUGATE | Califia Pharma Inc. (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230159766-A1 | CONDUCTIVE POLYMER COMPOSITION, SUBSTRATE, AND METHOD FOR PRODUCING SUBSTRATE | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-05-25 | — | — | US | disclosed |
| US-11576876-B2 | Affinity Medicant Conjugate | AF CHEMICALS, LLC (US) | 2023-02-14 | — | — | US | disclosed |
| US-20220133649-A1 | AFFINITY MEDICANT CONJUGATE | Califia Pharma Inc. (US) | 2022-05-05 | — | — | US | disclosed |
| US-20210380738-A1 | CONDUCTIVE POLYMER COMPOSITION, SUBSTRATE, AND METHOD FOR PRODUCING SUBSTRATE | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2021-12-09 | — | — | US | disclosed |
| CN-112105654-A | Curable resin mixture, curable resin composition, and cured product thereof | 日本化药株式会社 | 2020-12-18 | — | — | CN | disclosed |
| US-20200259094-A1 | CONDUCTIVE POLYMER COMPOSITE AND CONDUCTIVE POLYMER COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2020-08-13 | — | — | US | disclosed |
| WO-2004108683-A1 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
| CN-1538975-A | Metallocene catalysts containing idenyl moiety substituted at the 4-5-6-or 7-position by siloxy or germyloxy group | — | 2004-10-20 | — | — | CN | disclosed |
| US-20040152882-A1 | Metallocene catalysts containing an idenyl moiety substituted at the 4,-5,-6- or 7-position by a siloxy or germyloxy group | BOREALIS TECHNOLOGY OY (FI) | 2004-08-05 | — | — | US | disclosed |
| CN-1516690-A | Heterocyclic derivatives and medicines | �ձ���ҩ��ʽ���� | 2004-07-28 | — | — | CN | disclosed |
| EP-1401880-A1 | METALLOCENE CATALYSTS CONTAINING AN INDENYL MOIETY SUBSTITUTED AT THE 4-, 5-, 6- OR 7-POSITION BY A SILOXY OR GERMYLOXY GROUP | Borealis Technology Oy (FI) | 2004-03-31 | — | — | EP | disclosed |
| WO-2003000744-A1 | METALLOCENE CATALYSTS CONTAINING AN IDENYL MOIETY SUBSTITUTED AT THE 4-, 5-, 6- OR 7-POSITION BY A SILOXY OR GERMYLOXY GROUP | BOREALIS TECHNOLOGY OY (FI) | 2003-01-03 | — | — | WO | disclosed |
| US-4435397-A | ADRENERGIC BLOCKING AGENTS, 4-(3-ARYLOXY-2-HYDROXYPROPYL) SUBSTITUTED | NIPPON SHINYAKU CO., LTD. (JP) | 1984-03-06 | — | — | US | disclosed |
| US-4127675-A | BETA-RECEPTOR ANTAGONISTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1978-11-28 | — | — | US | disclosed |
| US-4045482-A | ADRENERGIC B-RECEPTOR BLOCKING AGENTS | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JA) | 1977-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12280021-B2 | Affinity medicant conjugate | FCER2, HDGF, FCGR2A | BCL2L1 1011/4885BAD 594/4885ALDH1A1 3966/4885 |
| US-20230372267-A1 | AFFINITY MEDICANT CONJUGATE | FCER2, HDGF, FCGR2A | BCL2L1 1011/4885BAD 594/4885ALDH1A1 3966/4885 |
| US-20220133649-A1 | AFFINITY MEDICANT CONJUGATE | FCER2, HDGF, FCGR2A | BCL2L1 1011/4885BAD 594/4885ALDH1A1 3966/4885 |
| US-20040152882-A1 | Metallocene catalysts containing an idenyl moiety substituted at the 4,-5,-6- or 7-position by a siloxy or germyloxy group | IPO4, GEMIN4, GEMIN5 | BCL2L1 2789/4885BAD 3791/4885ALDH1A1 1415/4885 |
| US-11576876-B2 | Affinity Medicant Conjugate | FCER2, HDGF, FCGR2A | BCL2L1 1011/4885BAD 594/4885ALDH1A1 3966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.